Urgent.News

What's breaking now, across thousands of outlets.

More in Business

Samsung Biologics Bets on Peptides with Trillion-Won Rights Offering

Samsung Biologics is undertaking a massive paid-in capital increase worth 3 trillion won (about $2.17 billion) to fully initiate the acquisition of ‘PolyPeptide Group,’ a Swiss company specializing in…

  • Samsung Biologics raises 3 trillion won to acquire PolyPeptide Group
  • Deal aims to dominate rapidly growing peptide market
  • Post-acquisition, Samsung to have 1.385 million liters production capacity by 2032

More from Friday 28 August →